GeneBio Systems
Recombinant Human MEK2/MAP2K2/MKK2 Protein (GST Tag)
Recombinant Human MEK2/MAP2K2/MKK2 Protein (GST Tag)
SKU:PKSH031494
Couldn't load pickup availability
Size: 50μg
Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Exp date: 12 months
Category ID_II: Recombinant Proteins
Category ID_III: Others
Abbreviation:
Target Synonym: CFC4;FLJ26075;MAPKK2;MEK2;MKK2;PRKMK2
Research Areas: Signal Transduction;Cancer;
Conjugation:
Target Species: Human
Expression Host: Baculovirus-Insect Cells
Application:
Fusion tag: N-GST
UNIProt ID: P36507
Accession: NP_109587.1
Background: Dual specificity mitogen-activated protein kinase kinase 2, also known as MAP kinase kinase 2, MAPKK2, ERK activator kinase 2, MAPK / ERK kinase 2, MEK2 and MAP2K2, is a member of the protein kinase superfamily, STE Ser/Thr protein kinase family and MAP kinase kinase subfamily. MAP2K2 / MEK2 contains oneprotein kinase domain. MEK1 and MEK2 (also known as MAP2K1 and MAP2K2, respectively) are evolutionarily conserved, dual-specificity kinases that mediate Erk1 and Erk2 activation during adhesion and growth factor signaling. MAP2K1 / MEK1 is a crucial modulator of Mek and Erk signaling and have potential implications for the role of MEK1 and MEK2 in tumorigenesis. MAP2K2 / MEK2 catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. It also activates the ERK1 and ERK2 MAP kinases. Defects in MAP2K2 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) which is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy.
Concentration:
Activity: Not validated for activity
Sequence: Met 1-Val 400
Purity: > 92 % as determined by reducing SDS-PAGE.
Formulation: Lyophilized from sterile 20mM Tris, 500mM NaCl, 2mM GSH, pH 7.4
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Reconstitution: Please refer to the printed manual for detailed information.
Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
Calculated MW: 70.7 kDa
ObservedMW: 66 kDa
